lair1 Search Results


93
Hycult Biotech mouse anti human lair1
Figure 3. The binding of PTIC to <t>LAIR1</t> induces downregulation of STAT1 phosphorylation. (A) Western blotting of the relative expression of STAT1 and pSTAT1. The bands were analyzed based on normalization to actin expression to eliminate inconsistencies caused by the amount of protein in the lane. (B) Relative expression of STAT1 and pSTAT1. Both were normalized for actin and were ad- justed to 1 unit. (C) Effect of STAT1 phosphorylation by activating LAIR1 with anti-LAIR1 antibody in M1. The bands were analyzed based on normalization to actin expression to eliminate inconsistencies caused by the amount of protein in the lane. (D) Relative expression of phosphorylated STAT1.
Mouse Anti Human Lair1, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/LAIR-1%2C+Human%2C+mAb+NKTA255/pm39940787-291-4-7
Average 93 stars, based on 1 article reviews
mouse anti human lair1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Miltenyi Biotec anti human lair 1 viobright fitc

Anti Human Lair 1 Viobright Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/CD305+(LAIR-1)+Antibody%2C+anti-human%2C+REAfinity/pmc10897522-30-0-8
Average 93 stars, based on 1 article reviews
anti human lair 1 viobright fitc - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

91
R&D Systems anti human lair1
Figure 4. Phosphorylation of human <t>LAIR1</t> by citrullinated collagen. Jurkat cells that overexpress the human LAIR1 (hLAIR1) were stimulated with PBS, collagen (200 µg/mL), or citrullinated collagen (200 µg/mL) for 5 min. Human LAIR1 was immunoprecipitated from 500 µg of total proteins by anti-human LAIR1 antibody (α-hLAIR1 (NKTA255), Thermo Fisher) using protein A/G bead. Phosphorylation of human LAIR1 was examined with the anti-phosphotyrosine antibody (α -pTyr 4G10, Millipore Human LAIR1 was used as control. The left panel represents type I collagen, and the right panel represents type II collagen. Data are representative of three separate analyses.
Anti Human Lair1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/Human+LAIR1+Antibody/pm36077232-201-5-15
Average 91 stars, based on 1 article reviews
anti human lair1 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology mouse monoclonal anti lair 1 sc 59281
Figure 4. Phosphorylation of human <t>LAIR1</t> by citrullinated collagen. Jurkat cells that overexpress the human LAIR1 (hLAIR1) were stimulated with PBS, collagen (200 µg/mL), or citrullinated collagen (200 µg/mL) for 5 min. Human LAIR1 was immunoprecipitated from 500 µg of total proteins by anti-human LAIR1 antibody (α-hLAIR1 (NKTA255), Thermo Fisher) using protein A/G bead. Phosphorylation of human LAIR1 was examined with the anti-phosphotyrosine antibody (α -pTyr 4G10, Millipore Human LAIR1 was used as control. The left panel represents type I collagen, and the right panel represents type II collagen. Data are representative of three separate analyses.
Mouse Monoclonal Anti Lair 1 Sc 59281, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/LAIR-1+Antibody/pmc03675607-253-123-127
Average 93 stars, based on 1 article reviews
mouse monoclonal anti lair 1 sc 59281 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc lair 1
Figure 4. Phosphorylation of human <t>LAIR1</t> by citrullinated collagen. Jurkat cells that overexpress the human LAIR1 (hLAIR1) were stimulated with PBS, collagen (200 µg/mL), or citrullinated collagen (200 µg/mL) for 5 min. Human LAIR1 was immunoprecipitated from 500 µg of total proteins by anti-human LAIR1 antibody (α-hLAIR1 (NKTA255), Thermo Fisher) using protein A/G bead. Phosphorylation of human LAIR1 was examined with the anti-phosphotyrosine antibody (α -pTyr 4G10, Millipore Human LAIR1 was used as control. The left panel represents type I collagen, and the right panel represents type II collagen. Data are representative of three separate analyses.
Lair 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/LAIR-1+Antibody/pm39868839-128-12-24
Average 94 stars, based on 1 article reviews
lair 1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
R&D Systems anti lair1 antibody
Relationship between <t>LAIR1</t> expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.
Anti Lair1 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/LAIR1+Antibody/pmc06642411-118-44-46
Average 90 stars, based on 1 article reviews
anti lair1 antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc antibodies against atg5
DCN promoted autophagy in ARPE-19 cells. (a and b) The protein level of <t>ATG5,</t> p62, and LC3 in ARPE-19 cells. ARPE-19 cells were treated with DCN in indicated concentrations for 24 h. The densities of ATG5/ β -actin, p62/ β -actin, and LC3II/LC3I were analyzed. (c and d) The protein level of ATG5, p62, and LC3 in ARPE-19 cells treated with 100 nM DCN in the presence of 5 mM 3-MA. The densities of ATG5/ β -actin, p62/ β -actin, and LC3II/LC3I were analyzed. (e) The ultrastructures in ARPE-19 cells were examined by transmission electron microscopy (TEM). The orange arrow indicates autophagosome and autolysosomes in the cytoplasm. (f and g) The protein level of ATG5, p62, and LC3 in ARPE-19 cells treated with 100 nM DCN in the presence of 0.1 μ M bafilomycin A1 (Baf). The densities of ATG5/ β -actin, p62/ β -actin, and LC3-II/LC3-I were analyzed. (h) ARPE-19 cells were transfected with mRFP-GFP-LC3 and subjected to 100 nM DCN treatment. Data is shown as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
Antibodies Against Atg5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/LAIR-1+XP+Rabbit+mAb/pmc08983248-47-19-27
Average 93 stars, based on 1 article reviews
antibodies against atg5 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

92
R&D Systems human lair1 duoset elisa kit
Fig. 1. <t>LAIR1</t> mRNA and protein levels are reduced in placentas from women with early onset preeclampsia or small for gestational age. (A) LAIR1 mRNA expression was significantly reduced in placentas from women with early onset preeclampsia (blue triangles, n = 78), compared to gestation matched controls (black dots, n = 30). (B) LAIR1 mRNA expression was significantly reduced in placentas from women who delivered an infant small for gestational age (SGA; <10th birthweight centile, red diamonds, n = 32) compared to gestation matched controls (black dots, n = 30). (C) LAIR1 protein expression was significantly reduced in placentas from women with early onset preeclampsia (blue triangles, n = 43), compared to gestation matched controls (black dots, n = 21). (D) LAIR1 protein expression was significantly reduced in placentas from women who delivered an SGA infant (red diamonds, n = 10) compared to gestation matched controls (black dots, n = 21). Data points represent individual patients. Data are presented as box and whisker plot. **P < 0.01, ****P < 0.0001.
Human Lair1 Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/Human+LAIR1+DuoSet+ELISA/pm39216164-48-12-18
Average 92 stars, based on 1 article reviews
human lair1 duoset elisa kit - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

94
R&D Systems recombinant human lair1
Relationship between <t>LAIR1</t> expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.
Recombinant Human Lair1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/Recombinant+Human+LAIR1+Fc+Chimera+Protein%2C+CF/pmc06642411-84-18-25
Average 94 stars, based on 1 article reviews
recombinant human lair1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
R&D Systems human lair1 elisa matched antibody pair
Relationship between <t>LAIR1</t> expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.
Human Lair1 Elisa Matched Antibody Pair, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/Human+LAIR1+Antibody/pmc06642411-84-11-25
Average 90 stars, based on 1 article reviews
human lair1 elisa matched antibody pair - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Proteintech anti lair 1
Relationship between <t>LAIR1</t> expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.
Anti Lair 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lair1/LAIR1+Antibody/pmc09844621-133-8-13
Average 93 stars, based on 1 article reviews
anti lair 1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


Figure 3. The binding of PTIC to LAIR1 induces downregulation of STAT1 phosphorylation. (A) Western blotting of the relative expression of STAT1 and pSTAT1. The bands were analyzed based on normalization to actin expression to eliminate inconsistencies caused by the amount of protein in the lane. (B) Relative expression of STAT1 and pSTAT1. Both were normalized for actin and were ad- justed to 1 unit. (C) Effect of STAT1 phosphorylation by activating LAIR1 with anti-LAIR1 antibody in M1. The bands were analyzed based on normalization to actin expression to eliminate inconsistencies caused by the amount of protein in the lane. (D) Relative expression of phosphorylated STAT1.

Journal: International journal of molecular sciences

Article Title: Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID.

doi: 10.3390/ijms26031018

Figure Lengend Snippet: Figure 3. The binding of PTIC to LAIR1 induces downregulation of STAT1 phosphorylation. (A) Western blotting of the relative expression of STAT1 and pSTAT1. The bands were analyzed based on normalization to actin expression to eliminate inconsistencies caused by the amount of protein in the lane. (B) Relative expression of STAT1 and pSTAT1. Both were normalized for actin and were ad- justed to 1 unit. (C) Effect of STAT1 phosphorylation by activating LAIR1 with anti-LAIR1 antibody in M1. The bands were analyzed based on normalization to actin expression to eliminate inconsistencies caused by the amount of protein in the lane. (D) Relative expression of phosphorylated STAT1.

Article Snippet: Subsequently, a 1:500 dilution mouse anti-human LAIR1 (HycultBiotech # HM2364-100UG) was added overnight at 4 ◦C.

Techniques: Binding Assay, Phospho-proteomics, Western Blot, Expressing

Figure 4. Representative flow plots of circulating Mo1 subset in SARS-CoV2-infected symptomatic outpatients at the baseline 8, 15, and 90 days post-treatment with PTIC (n = 20) or a placebo (n = 20). CD86+/CD11c+/CD3−/IP-10+-expressing cells in (A) healthy donors and patients at (B) the baseline, (C) 8 days, (D) 15 days, and (E) 90 days post-treatment. (F) Flow plots at the baseline (red) and 90 days post-treatment with PTIC (blue). (G) CD86+/CD11c+/CD3−/IP-10+-producing cells are expressed as a mean ± SEM. (H) CD14+/CD11c+/CD86+/LAIR1+-producing cells are expressed as a mean ± SEM. Blue stars show the day the treatment reached p < 0.05 compared to the PTIC treatment baseline. Pink stars depict the day the therapy reached p < 0.05 compared to the baseline for the placebo. The numbers on the graph represent the statistical significance between the patients treated with PTIC vs. the placebo. ** p ≤0.001 depict statistically significant differences from the baseline (blue: PTIC, pink: placebo, green: healthy donors).

Journal: International journal of molecular sciences

Article Title: Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID.

doi: 10.3390/ijms26031018

Figure Lengend Snippet: Figure 4. Representative flow plots of circulating Mo1 subset in SARS-CoV2-infected symptomatic outpatients at the baseline 8, 15, and 90 days post-treatment with PTIC (n = 20) or a placebo (n = 20). CD86+/CD11c+/CD3−/IP-10+-expressing cells in (A) healthy donors and patients at (B) the baseline, (C) 8 days, (D) 15 days, and (E) 90 days post-treatment. (F) Flow plots at the baseline (red) and 90 days post-treatment with PTIC (blue). (G) CD86+/CD11c+/CD3−/IP-10+-producing cells are expressed as a mean ± SEM. (H) CD14+/CD11c+/CD86+/LAIR1+-producing cells are expressed as a mean ± SEM. Blue stars show the day the treatment reached p < 0.05 compared to the PTIC treatment baseline. Pink stars depict the day the therapy reached p < 0.05 compared to the baseline for the placebo. The numbers on the graph represent the statistical significance between the patients treated with PTIC vs. the placebo. ** p ≤0.001 depict statistically significant differences from the baseline (blue: PTIC, pink: placebo, green: healthy donors).

Article Snippet: Subsequently, a 1:500 dilution mouse anti-human LAIR1 (HycultBiotech # HM2364-100UG) was added overnight at 4 ◦C.

Techniques: Infection, Expressing

Figure 5. Representative flow plots of circulating Mo2 subset in SARS-CoV2-infected symptomatic outpatients at the baseline 8, 15, and 90 days post-treatment with PTIC (n = 20) or a placebo (n = 20). CD11b+/CD16+/CD163+/IDO+-expressing cells in (A) healthy donors and patients at (B) the base- line, (C) 8 days, (D) 15 days, and (E) 90 days post-treatment. (F) Flow plots at the baseline (red) and 90 days post-treatment with PTIC (blue). (G) CD16+/CD11b+/CD163+/IDO+-producing cells are expressed as a mean ± SEM. (H) CD16+/CD11b+/CD163+/LAIR1+-producing cells are expressed as a mean ± SEM. Blue stars show the day the treatment reached p < 0.05 compared to the PTIC treatment the baseline. Pink stars depict the day the treatment reached p < 0.05 compared to the baseline for the placebo. The numbers on the graph represent the statistical significance between the patients treated with PTIC vs. the placebo. * p ≤0.05 and ** p ≤0.001 depict statistically significant differences from the baseline (blue: PTIC, pink: placebo, green: healthy donors).

Journal: International journal of molecular sciences

Article Title: Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID.

doi: 10.3390/ijms26031018

Figure Lengend Snippet: Figure 5. Representative flow plots of circulating Mo2 subset in SARS-CoV2-infected symptomatic outpatients at the baseline 8, 15, and 90 days post-treatment with PTIC (n = 20) or a placebo (n = 20). CD11b+/CD16+/CD163+/IDO+-expressing cells in (A) healthy donors and patients at (B) the base- line, (C) 8 days, (D) 15 days, and (E) 90 days post-treatment. (F) Flow plots at the baseline (red) and 90 days post-treatment with PTIC (blue). (G) CD16+/CD11b+/CD163+/IDO+-producing cells are expressed as a mean ± SEM. (H) CD16+/CD11b+/CD163+/LAIR1+-producing cells are expressed as a mean ± SEM. Blue stars show the day the treatment reached p < 0.05 compared to the PTIC treatment the baseline. Pink stars depict the day the treatment reached p < 0.05 compared to the baseline for the placebo. The numbers on the graph represent the statistical significance between the patients treated with PTIC vs. the placebo. * p ≤0.05 and ** p ≤0.001 depict statistically significant differences from the baseline (blue: PTIC, pink: placebo, green: healthy donors).

Article Snippet: Subsequently, a 1:500 dilution mouse anti-human LAIR1 (HycultBiotech # HM2364-100UG) was added overnight at 4 ◦C.

Techniques: Infection, Expressing

Figure 8. PTIC regulates STAT1 phosphorylation through LAIR1 in M1 and favors polarization towards M2. (A) Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1 or CD305) is a type I transmembrane glycoprotein that contains one extracellular Ig-like domain and two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its intracellular domain. LAIR1 is expressed in most hematopoietic lineages, including monocytes, macrophages, dendritic cells (DCs), natural killer (NK) cells, and many T and B cell populations. Its extracellular domain binds to glycine–proline– hydroxyproline collagen repeats, and its ITIMs recruit the phosphatases SHP1 and SHP2. Collagens, C1q, MBL, surface protein-D (SP-D), Rifins, and Colec12 have been reported as ligands for LAIR1. It downregulates T, B, and natural killer (NK) cell functions by the recruitment of the SHP1 and SHP2 phosphatases. (B) The pre-polarized (M0) macrophage subsets challenge LPS/IFN-γ and induce polarization to M1. The human monocytic cell line THP-1 expresses high levels of LAIR1. (C) LAIR1

Journal: International journal of molecular sciences

Article Title: Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID.

doi: 10.3390/ijms26031018

Figure Lengend Snippet: Figure 8. PTIC regulates STAT1 phosphorylation through LAIR1 in M1 and favors polarization towards M2. (A) Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1 or CD305) is a type I transmembrane glycoprotein that contains one extracellular Ig-like domain and two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its intracellular domain. LAIR1 is expressed in most hematopoietic lineages, including monocytes, macrophages, dendritic cells (DCs), natural killer (NK) cells, and many T and B cell populations. Its extracellular domain binds to glycine–proline– hydroxyproline collagen repeats, and its ITIMs recruit the phosphatases SHP1 and SHP2. Collagens, C1q, MBL, surface protein-D (SP-D), Rifins, and Colec12 have been reported as ligands for LAIR1. It downregulates T, B, and natural killer (NK) cell functions by the recruitment of the SHP1 and SHP2 phosphatases. (B) The pre-polarized (M0) macrophage subsets challenge LPS/IFN-γ and induce polarization to M1. The human monocytic cell line THP-1 expresses high levels of LAIR1. (C) LAIR1

Article Snippet: Subsequently, a 1:500 dilution mouse anti-human LAIR1 (HycultBiotech # HM2364-100UG) was added overnight at 4 ◦C.

Techniques: Phospho-proteomics

Journal: Cell Reports Medicine

Article Title: Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

doi: 10.1016/j.xcrm.2023.101380

Figure Lengend Snippet:

Article Snippet: anti-human LAIR-1-VioBright-FITC (clone REA447) – Lab 1 , Miltenyi Biotec , Cat# 130-106-852; RRID: AB_2657221.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Staining, Cell Isolation, Amplification, Multiplexing, Expressing, Software

Figure 4. Phosphorylation of human LAIR1 by citrullinated collagen. Jurkat cells that overexpress the human LAIR1 (hLAIR1) were stimulated with PBS, collagen (200 µg/mL), or citrullinated collagen (200 µg/mL) for 5 min. Human LAIR1 was immunoprecipitated from 500 µg of total proteins by anti-human LAIR1 antibody (α-hLAIR1 (NKTA255), Thermo Fisher) using protein A/G bead. Phosphorylation of human LAIR1 was examined with the anti-phosphotyrosine antibody (α -pTyr 4G10, Millipore Human LAIR1 was used as control. The left panel represents type I collagen, and the right panel represents type II collagen. Data are representative of three separate analyses.

Journal: International journal of molecular sciences

Article Title: Role of Citrullinated Collagen in Autoimmune Arthritis.

doi: 10.3390/ijms23179833

Figure Lengend Snippet: Figure 4. Phosphorylation of human LAIR1 by citrullinated collagen. Jurkat cells that overexpress the human LAIR1 (hLAIR1) were stimulated with PBS, collagen (200 µg/mL), or citrullinated collagen (200 µg/mL) for 5 min. Human LAIR1 was immunoprecipitated from 500 µg of total proteins by anti-human LAIR1 antibody (α-hLAIR1 (NKTA255), Thermo Fisher) using protein A/G bead. Phosphorylation of human LAIR1 was examined with the anti-phosphotyrosine antibody (α -pTyr 4G10, Millipore Human LAIR1 was used as control. The left panel represents type I collagen, and the right panel represents type II collagen. Data are representative of three separate analyses.

Article Snippet: In western blot studies, the anti-human LAIR1 and the anti-phospho-tyrosine specific antibodies were purchased from R&D Systems, Inc. (Minneapolis, MN, USA).

Techniques: Phospho-proteomics, Immunoprecipitation, Control

Relationship between LAIR1 expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.

Journal: EBioMedicine

Article Title: Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling

doi: 10.1016/j.ebiom.2019.06.040

Figure Lengend Snippet: Relationship between LAIR1 expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.

Article Snippet: Following electrophoresis, proteins were electrotransferred to iBlot 2 nitrocellulose Mini Stacks (Life Technologies, Carlsbad, CA), and subsequently blocked with 5% blotting grade nonfat dry milk (Bio-Rad Laboratories) in PBS and 0.01% Tween 20 (PBST) at RT for 1 h. Membranes were then probed with anti-LAIR1 antibody (R&D Systems, Inc. Minneapolis, MN) dissolved in fresh blocking buffer.

Techniques: Expressing, MANN-WHITNEY, Western Blot

Effect of intraleukocytic Pf Hz on LAIR1 and SHP-1 phosphorylation. Temporal kinetics of the signalling pathway in response to the different treatment conditions was determined in PBMCs from malaria-naïve donors (n = 6, measured in triplicate). (a) Human Phospho-immunoreceptor array results showing LAIR1 and SHP-1 phosphorylation upon no treatment (baseline), C1q (25 μg/mL), Pf Hz (10 μg/mL), and Pf Hz + C1q. Phosphorylation (spots) in the different conditions with control represented by blue boxes, LAIR1 by red boxes, and SHP-1 by green boxes. (b) Densitometric analysis of human phosphor-immunoreceptor array data. Data presented as (mean ± SEM). Across group comparisons analysed using ANOVA. *indicates significant differences ( P < .05) determined by Student t-test in pLAIR1 and pSHP-1 compared to C1q treatment. Phagocytosis of Pf Hz resulted in a reduction of pLAIR1 relative to C1q (alone) treatment. Similarly, ingestion of Pf Hz also caused a marked decrease in pSHP-1 levels relative to C1q treatment. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Journal: EBioMedicine

Article Title: Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling

doi: 10.1016/j.ebiom.2019.06.040

Figure Lengend Snippet: Effect of intraleukocytic Pf Hz on LAIR1 and SHP-1 phosphorylation. Temporal kinetics of the signalling pathway in response to the different treatment conditions was determined in PBMCs from malaria-naïve donors (n = 6, measured in triplicate). (a) Human Phospho-immunoreceptor array results showing LAIR1 and SHP-1 phosphorylation upon no treatment (baseline), C1q (25 μg/mL), Pf Hz (10 μg/mL), and Pf Hz + C1q. Phosphorylation (spots) in the different conditions with control represented by blue boxes, LAIR1 by red boxes, and SHP-1 by green boxes. (b) Densitometric analysis of human phosphor-immunoreceptor array data. Data presented as (mean ± SEM). Across group comparisons analysed using ANOVA. *indicates significant differences ( P < .05) determined by Student t-test in pLAIR1 and pSHP-1 compared to C1q treatment. Phagocytosis of Pf Hz resulted in a reduction of pLAIR1 relative to C1q (alone) treatment. Similarly, ingestion of Pf Hz also caused a marked decrease in pSHP-1 levels relative to C1q treatment. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Following electrophoresis, proteins were electrotransferred to iBlot 2 nitrocellulose Mini Stacks (Life Technologies, Carlsbad, CA), and subsequently blocked with 5% blotting grade nonfat dry milk (Bio-Rad Laboratories) in PBS and 0.01% Tween 20 (PBST) at RT for 1 h. Membranes were then probed with anti-LAIR1 antibody (R&D Systems, Inc. Minneapolis, MN) dissolved in fresh blocking buffer.

Techniques: Phospho-proteomics, Control

LAIR1 signalling pathway in malaria. The LAIR1 pathway is activated by attachment of collagen and collagenous ligands (C1q) to LAIR1 extracellular surface. This results in phosphorylation of intracellular LAIR1 ITIM tyrosine residues by Src family kinases. Phosphorylated ITIMs serve as docking sites for recruitment of SHP-1 and SHP-2 phosphatases. SHP-1 and SHP-2 become localized to phosphorylated ITIMs through their regulatory SH2 domains, subsequently inducing their phosphatase activity. Activated SHP-1 has been shown to block activation and nuclear translocation of nuclear factor nuclear factor-kappa beta (NF-κB) through de-phosphorylation of inhibitor of kappa-beta kinase complex (IKK). SHP-1 phosphatase activity also inhibits activation and translocation of IRFs from the cytoplasm to the nucleus by preventing TANK-binding kinase 1 (TANK-1) phosphorylation of interferon regulatory factors (IRFs). These events subsequently block transcription of inflammatory mediator encoding genes with response elements for IRFs and NF-κB. SHP-2 inhibits activation of IRF 8 and blocks expression of phagocyte NADPH oxidase (gp91 PHOX ). LAIR1 inhibitory signalling is regulated by soluble LAIR1 and LAIR2 (soluble homolog of LAIR1) through competition for collagenous ligands. Children with SMA had increased circulating levels of sLAIR1 and sLAIR2 indicative of enhanced receptor shedding. C1q was reduced in children with SMA, thereby, limiting ligand availability. Phagocytosis of Pf Hz antagonizes LAIR1 signalling through down-regulation of LAIR1 ITIM and SHP-1 phosphorylation, but does not alter SHP-2 phosphorylation. Leukocytic ingestion of Pf Hz also decreases LAIR1 transcripts and protein. These events result in NF-κB activation and the consequent production of pro-inflammatory mediators that enhance the pathogenesis of SMA. Red arrows represent ligand-receptor interaction, black solid arrows represent activation, and dashed black arrows represent blockade. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Journal: EBioMedicine

Article Title: Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling

doi: 10.1016/j.ebiom.2019.06.040

Figure Lengend Snippet: LAIR1 signalling pathway in malaria. The LAIR1 pathway is activated by attachment of collagen and collagenous ligands (C1q) to LAIR1 extracellular surface. This results in phosphorylation of intracellular LAIR1 ITIM tyrosine residues by Src family kinases. Phosphorylated ITIMs serve as docking sites for recruitment of SHP-1 and SHP-2 phosphatases. SHP-1 and SHP-2 become localized to phosphorylated ITIMs through their regulatory SH2 domains, subsequently inducing their phosphatase activity. Activated SHP-1 has been shown to block activation and nuclear translocation of nuclear factor nuclear factor-kappa beta (NF-κB) through de-phosphorylation of inhibitor of kappa-beta kinase complex (IKK). SHP-1 phosphatase activity also inhibits activation and translocation of IRFs from the cytoplasm to the nucleus by preventing TANK-binding kinase 1 (TANK-1) phosphorylation of interferon regulatory factors (IRFs). These events subsequently block transcription of inflammatory mediator encoding genes with response elements for IRFs and NF-κB. SHP-2 inhibits activation of IRF 8 and blocks expression of phagocyte NADPH oxidase (gp91 PHOX ). LAIR1 inhibitory signalling is regulated by soluble LAIR1 and LAIR2 (soluble homolog of LAIR1) through competition for collagenous ligands. Children with SMA had increased circulating levels of sLAIR1 and sLAIR2 indicative of enhanced receptor shedding. C1q was reduced in children with SMA, thereby, limiting ligand availability. Phagocytosis of Pf Hz antagonizes LAIR1 signalling through down-regulation of LAIR1 ITIM and SHP-1 phosphorylation, but does not alter SHP-2 phosphorylation. Leukocytic ingestion of Pf Hz also decreases LAIR1 transcripts and protein. These events result in NF-κB activation and the consequent production of pro-inflammatory mediators that enhance the pathogenesis of SMA. Red arrows represent ligand-receptor interaction, black solid arrows represent activation, and dashed black arrows represent blockade. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Following electrophoresis, proteins were electrotransferred to iBlot 2 nitrocellulose Mini Stacks (Life Technologies, Carlsbad, CA), and subsequently blocked with 5% blotting grade nonfat dry milk (Bio-Rad Laboratories) in PBS and 0.01% Tween 20 (PBST) at RT for 1 h. Membranes were then probed with anti-LAIR1 antibody (R&D Systems, Inc. Minneapolis, MN) dissolved in fresh blocking buffer.

Techniques: Phospho-proteomics, Activity Assay, Blocking Assay, Activation Assay, Translocation Assay, De-Phosphorylation Assay, Binding Assay, Expressing

DCN promoted autophagy in ARPE-19 cells. (a and b) The protein level of ATG5, p62, and LC3 in ARPE-19 cells. ARPE-19 cells were treated with DCN in indicated concentrations for 24 h. The densities of ATG5/ β -actin, p62/ β -actin, and LC3II/LC3I were analyzed. (c and d) The protein level of ATG5, p62, and LC3 in ARPE-19 cells treated with 100 nM DCN in the presence of 5 mM 3-MA. The densities of ATG5/ β -actin, p62/ β -actin, and LC3II/LC3I were analyzed. (e) The ultrastructures in ARPE-19 cells were examined by transmission electron microscopy (TEM). The orange arrow indicates autophagosome and autolysosomes in the cytoplasm. (f and g) The protein level of ATG5, p62, and LC3 in ARPE-19 cells treated with 100 nM DCN in the presence of 0.1 μ M bafilomycin A1 (Baf). The densities of ATG5/ β -actin, p62/ β -actin, and LC3-II/LC3-I were analyzed. (h) ARPE-19 cells were transfected with mRFP-GFP-LC3 and subjected to 100 nM DCN treatment. Data is shown as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Decorin Protects Retinal Pigment Epithelium Cells from Oxidative Stress and Apoptosis via AMPK-mTOR-Regulated Autophagy

doi: 10.1155/2022/3955748

Figure Lengend Snippet: DCN promoted autophagy in ARPE-19 cells. (a and b) The protein level of ATG5, p62, and LC3 in ARPE-19 cells. ARPE-19 cells were treated with DCN in indicated concentrations for 24 h. The densities of ATG5/ β -actin, p62/ β -actin, and LC3II/LC3I were analyzed. (c and d) The protein level of ATG5, p62, and LC3 in ARPE-19 cells treated with 100 nM DCN in the presence of 5 mM 3-MA. The densities of ATG5/ β -actin, p62/ β -actin, and LC3II/LC3I were analyzed. (e) The ultrastructures in ARPE-19 cells were examined by transmission electron microscopy (TEM). The orange arrow indicates autophagosome and autolysosomes in the cytoplasm. (f and g) The protein level of ATG5, p62, and LC3 in ARPE-19 cells treated with 100 nM DCN in the presence of 0.1 μ M bafilomycin A1 (Baf). The densities of ATG5/ β -actin, p62/ β -actin, and LC3-II/LC3-I were analyzed. (h) ARPE-19 cells were transfected with mRFP-GFP-LC3 and subjected to 100 nM DCN treatment. Data is shown as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: Subsequently, the transferred membrane was blocked with bovine serum albumin for 1 h and incubated with the following primary antibodies against ATG5 (60061-1-Ig, PTG, China), LC3 (12741, CST, USA), p62 (5114, CST, USA), BAX (50599-2-Ig, PTG, China), Bcl-2 (12789-1-AP, PTG, China), cleaved-caspase 3 (5A1E, CST, USA), AMPK(5831, CST, USA), p-AMPK(50081, CST, USA), mTOR(2983, CST, USA), p-mTOR(5536, CST, USA), p70S6K(9202, CST, USA), p-p70S6K(97596, CST, USA), and β -actin (4970, CST, USA).

Techniques: Transmission Assay, Electron Microscopy, Transfection

Protective effect of DCN against oxidative stress was dependent on autophagy. ARPE-19 cells were first transfected with ATG5 siRNA and received different treatments. (a and b) The expression level of ATG5 in ARPE-19 cells after ATG5 small interfering RNA (siRNA) transfection. The densities of ATG5/ β -actin were analyzed. (c and d) The protein levels of ATG5, p62, and LC3 in ARPE-19 cells in the presence of ATG5 siRNA transfection followed by treatment of DCN under the stimulation of H 2 O 2 . (e) CLSM images of ARPE-19 cells using ROS detection probes as indicators. (f) ROS analysis with flow cytometry and quantitative analysis of ROS fluorescence intensity. (g) The expression level of MDA, SOD, and GSH following indicated treatment. Data is shown as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Decorin Protects Retinal Pigment Epithelium Cells from Oxidative Stress and Apoptosis via AMPK-mTOR-Regulated Autophagy

doi: 10.1155/2022/3955748

Figure Lengend Snippet: Protective effect of DCN against oxidative stress was dependent on autophagy. ARPE-19 cells were first transfected with ATG5 siRNA and received different treatments. (a and b) The expression level of ATG5 in ARPE-19 cells after ATG5 small interfering RNA (siRNA) transfection. The densities of ATG5/ β -actin were analyzed. (c and d) The protein levels of ATG5, p62, and LC3 in ARPE-19 cells in the presence of ATG5 siRNA transfection followed by treatment of DCN under the stimulation of H 2 O 2 . (e) CLSM images of ARPE-19 cells using ROS detection probes as indicators. (f) ROS analysis with flow cytometry and quantitative analysis of ROS fluorescence intensity. (g) The expression level of MDA, SOD, and GSH following indicated treatment. Data is shown as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: Subsequently, the transferred membrane was blocked with bovine serum albumin for 1 h and incubated with the following primary antibodies against ATG5 (60061-1-Ig, PTG, China), LC3 (12741, CST, USA), p62 (5114, CST, USA), BAX (50599-2-Ig, PTG, China), Bcl-2 (12789-1-AP, PTG, China), cleaved-caspase 3 (5A1E, CST, USA), AMPK(5831, CST, USA), p-AMPK(50081, CST, USA), mTOR(2983, CST, USA), p-mTOR(5536, CST, USA), p70S6K(9202, CST, USA), p-p70S6K(97596, CST, USA), and β -actin (4970, CST, USA).

Techniques: Transfection, Expressing, Small Interfering RNA, Flow Cytometry, Fluorescence

DCN promoted autophagy through AMPK/mTOR signaling pathway. (a–d) The protein levels of p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, and p70S6K in ARPE-19 cells. ARPE-19 cells were treated with 5 mM compound C prior to DCN treatment. The densities of p-AMPK/AMPK, p-mTOR/mTOR, and P-p70S6K/p70S6K were analyzed. (e–g) The protein levels of p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, and p70S6K in ARPE-19 cells. ARPE-19 cells were treated with 5 μ M MHY1485 prior to DCN treatment. The densities of p-mTOR, mTOR, p-p70S6K, and p70S6K were analyzed. (h–k) The protein levels of ATG5, p62, and LC3 in ARPE-19 cells. ARPE-19 cells were treated with 5 mM compound C or 5 μ M MHY1485 prior to DCN treatment under oxidative stress. Data is shown as mean ± SD, ∗ p < 0.05, and ∗∗ p < 0.01.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Decorin Protects Retinal Pigment Epithelium Cells from Oxidative Stress and Apoptosis via AMPK-mTOR-Regulated Autophagy

doi: 10.1155/2022/3955748

Figure Lengend Snippet: DCN promoted autophagy through AMPK/mTOR signaling pathway. (a–d) The protein levels of p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, and p70S6K in ARPE-19 cells. ARPE-19 cells were treated with 5 mM compound C prior to DCN treatment. The densities of p-AMPK/AMPK, p-mTOR/mTOR, and P-p70S6K/p70S6K were analyzed. (e–g) The protein levels of p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, and p70S6K in ARPE-19 cells. ARPE-19 cells were treated with 5 μ M MHY1485 prior to DCN treatment. The densities of p-mTOR, mTOR, p-p70S6K, and p70S6K were analyzed. (h–k) The protein levels of ATG5, p62, and LC3 in ARPE-19 cells. ARPE-19 cells were treated with 5 mM compound C or 5 μ M MHY1485 prior to DCN treatment under oxidative stress. Data is shown as mean ± SD, ∗ p < 0.05, and ∗∗ p < 0.01.

Article Snippet: Subsequently, the transferred membrane was blocked with bovine serum albumin for 1 h and incubated with the following primary antibodies against ATG5 (60061-1-Ig, PTG, China), LC3 (12741, CST, USA), p62 (5114, CST, USA), BAX (50599-2-Ig, PTG, China), Bcl-2 (12789-1-AP, PTG, China), cleaved-caspase 3 (5A1E, CST, USA), AMPK(5831, CST, USA), p-AMPK(50081, CST, USA), mTOR(2983, CST, USA), p-mTOR(5536, CST, USA), p70S6K(9202, CST, USA), p-p70S6K(97596, CST, USA), and β -actin (4970, CST, USA).

Techniques:

Fig. 1. LAIR1 mRNA and protein levels are reduced in placentas from women with early onset preeclampsia or small for gestational age. (A) LAIR1 mRNA expression was significantly reduced in placentas from women with early onset preeclampsia (blue triangles, n = 78), compared to gestation matched controls (black dots, n = 30). (B) LAIR1 mRNA expression was significantly reduced in placentas from women who delivered an infant small for gestational age (SGA; <10th birthweight centile, red diamonds, n = 32) compared to gestation matched controls (black dots, n = 30). (C) LAIR1 protein expression was significantly reduced in placentas from women with early onset preeclampsia (blue triangles, n = 43), compared to gestation matched controls (black dots, n = 21). (D) LAIR1 protein expression was significantly reduced in placentas from women who delivered an SGA infant (red diamonds, n = 10) compared to gestation matched controls (black dots, n = 21). Data points represent individual patients. Data are presented as box and whisker plot. **P < 0.01, ****P < 0.0001.

Journal: Placenta

Article Title: Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is reduced with preeclampsia and small for gestational aged fetuses.

doi: 10.1016/j.placenta.2024.08.018

Figure Lengend Snippet: Fig. 1. LAIR1 mRNA and protein levels are reduced in placentas from women with early onset preeclampsia or small for gestational age. (A) LAIR1 mRNA expression was significantly reduced in placentas from women with early onset preeclampsia (blue triangles, n = 78), compared to gestation matched controls (black dots, n = 30). (B) LAIR1 mRNA expression was significantly reduced in placentas from women who delivered an infant small for gestational age (SGA; <10th birthweight centile, red diamonds, n = 32) compared to gestation matched controls (black dots, n = 30). (C) LAIR1 protein expression was significantly reduced in placentas from women with early onset preeclampsia (blue triangles, n = 43), compared to gestation matched controls (black dots, n = 21). (D) LAIR1 protein expression was significantly reduced in placentas from women who delivered an SGA infant (red diamonds, n = 10) compared to gestation matched controls (black dots, n = 21). Data points represent individual patients. Data are presented as box and whisker plot. **P < 0.01, ****P < 0.0001.

Article Snippet: Levels of LAIR1 in plasma and protein lysates were quantified using the Human LAIR1 DuoSet ELISA kit (DY2664–05, R&D System, Minnesota, USA) according to the manufacturer’s instructions.

Techniques: Expressing, Whisker Assay

Fig. 2. LAIR1 mRNA is reduced in placental explants exposed to hypoxia, but not inflammatory cytokines, IL6 or TNFα. Following IL6 treatment (10 ng/mL), LAIR1 mRNA expression (A) and protein expression in placental lysates (B), and media (C) of placental explants were not altered (red squares) compared to controls (0 ng/mL; black dots). Following TNFα treatment (10 ng/mL), LAIR1 mRNA expression (D) and protein expression in placental lysates (E), and media (F) of placental explants are not altered (blue squares) when compared to controls (black dots, 0 ng/mL). Following exposure to hypoxia (1 % O2), LAIR1 mRNA expression (G) is significantly reduced, while protein expression in placental lysates (H), and media (I) of placental explants were not significantly altered (green squares) compared to controls (black dots, 8 % O2). All experiments were done in triplicate, n = 5 patients. Data are presented as mean ± SEM. **P < 0.01.

Journal: Placenta

Article Title: Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is reduced with preeclampsia and small for gestational aged fetuses.

doi: 10.1016/j.placenta.2024.08.018

Figure Lengend Snippet: Fig. 2. LAIR1 mRNA is reduced in placental explants exposed to hypoxia, but not inflammatory cytokines, IL6 or TNFα. Following IL6 treatment (10 ng/mL), LAIR1 mRNA expression (A) and protein expression in placental lysates (B), and media (C) of placental explants were not altered (red squares) compared to controls (0 ng/mL; black dots). Following TNFα treatment (10 ng/mL), LAIR1 mRNA expression (D) and protein expression in placental lysates (E), and media (F) of placental explants are not altered (blue squares) when compared to controls (black dots, 0 ng/mL). Following exposure to hypoxia (1 % O2), LAIR1 mRNA expression (G) is significantly reduced, while protein expression in placental lysates (H), and media (I) of placental explants were not significantly altered (green squares) compared to controls (black dots, 8 % O2). All experiments were done in triplicate, n = 5 patients. Data are presented as mean ± SEM. **P < 0.01.

Article Snippet: Levels of LAIR1 in plasma and protein lysates were quantified using the Human LAIR1 DuoSet ELISA kit (DY2664–05, R&D System, Minnesota, USA) according to the manufacturer’s instructions.

Techniques: Expressing

Relationship between LAIR1 expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.

Journal: EBioMedicine

Article Title: Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling

doi: 10.1016/j.ebiom.2019.06.040

Figure Lengend Snippet: Relationship between LAIR1 expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.

Article Snippet: Soluble LAIR1 was measured in serum of study participants using the human LAIR1 ELISA matched antibody pair, and recombinant human LAIR1 (Creative Diagnostics, 45–16 Ramsey Rd, Shirley, NY 11967; Cat No. ABPR-0519).

Techniques: Expressing, MANN-WHITNEY, Western Blot

Effect of intraleukocytic Pf Hz on LAIR1 and SHP-1 phosphorylation. Temporal kinetics of the signalling pathway in response to the different treatment conditions was determined in PBMCs from malaria-naïve donors (n = 6, measured in triplicate). (a) Human Phospho-immunoreceptor array results showing LAIR1 and SHP-1 phosphorylation upon no treatment (baseline), C1q (25 μg/mL), Pf Hz (10 μg/mL), and Pf Hz + C1q. Phosphorylation (spots) in the different conditions with control represented by blue boxes, LAIR1 by red boxes, and SHP-1 by green boxes. (b) Densitometric analysis of human phosphor-immunoreceptor array data. Data presented as (mean ± SEM). Across group comparisons analysed using ANOVA. *indicates significant differences ( P < .05) determined by Student t-test in pLAIR1 and pSHP-1 compared to C1q treatment. Phagocytosis of Pf Hz resulted in a reduction of pLAIR1 relative to C1q (alone) treatment. Similarly, ingestion of Pf Hz also caused a marked decrease in pSHP-1 levels relative to C1q treatment. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Journal: EBioMedicine

Article Title: Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling

doi: 10.1016/j.ebiom.2019.06.040

Figure Lengend Snippet: Effect of intraleukocytic Pf Hz on LAIR1 and SHP-1 phosphorylation. Temporal kinetics of the signalling pathway in response to the different treatment conditions was determined in PBMCs from malaria-naïve donors (n = 6, measured in triplicate). (a) Human Phospho-immunoreceptor array results showing LAIR1 and SHP-1 phosphorylation upon no treatment (baseline), C1q (25 μg/mL), Pf Hz (10 μg/mL), and Pf Hz + C1q. Phosphorylation (spots) in the different conditions with control represented by blue boxes, LAIR1 by red boxes, and SHP-1 by green boxes. (b) Densitometric analysis of human phosphor-immunoreceptor array data. Data presented as (mean ± SEM). Across group comparisons analysed using ANOVA. *indicates significant differences ( P < .05) determined by Student t-test in pLAIR1 and pSHP-1 compared to C1q treatment. Phagocytosis of Pf Hz resulted in a reduction of pLAIR1 relative to C1q (alone) treatment. Similarly, ingestion of Pf Hz also caused a marked decrease in pSHP-1 levels relative to C1q treatment. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Soluble LAIR1 was measured in serum of study participants using the human LAIR1 ELISA matched antibody pair, and recombinant human LAIR1 (Creative Diagnostics, 45–16 Ramsey Rd, Shirley, NY 11967; Cat No. ABPR-0519).

Techniques:

LAIR1 signalling pathway in malaria. The LAIR1 pathway is activated by attachment of collagen and collagenous ligands (C1q) to LAIR1 extracellular surface. This results in phosphorylation of intracellular LAIR1 ITIM tyrosine residues by Src family kinases. Phosphorylated ITIMs serve as docking sites for recruitment of SHP-1 and SHP-2 phosphatases. SHP-1 and SHP-2 become localized to phosphorylated ITIMs through their regulatory SH2 domains, subsequently inducing their phosphatase activity. Activated SHP-1 has been shown to block activation and nuclear translocation of nuclear factor nuclear factor-kappa beta (NF-κB) through de-phosphorylation of inhibitor of kappa-beta kinase complex (IKK). SHP-1 phosphatase activity also inhibits activation and translocation of IRFs from the cytoplasm to the nucleus by preventing TANK-binding kinase 1 (TANK-1) phosphorylation of interferon regulatory factors (IRFs). These events subsequently block transcription of inflammatory mediator encoding genes with response elements for IRFs and NF-κB. SHP-2 inhibits activation of IRF 8 and blocks expression of phagocyte NADPH oxidase (gp91 PHOX ). LAIR1 inhibitory signalling is regulated by soluble LAIR1 and LAIR2 (soluble homolog of LAIR1) through competition for collagenous ligands. Children with SMA had increased circulating levels of sLAIR1 and sLAIR2 indicative of enhanced receptor shedding. C1q was reduced in children with SMA, thereby, limiting ligand availability. Phagocytosis of Pf Hz antagonizes LAIR1 signalling through down-regulation of LAIR1 ITIM and SHP-1 phosphorylation, but does not alter SHP-2 phosphorylation. Leukocytic ingestion of Pf Hz also decreases LAIR1 transcripts and protein. These events result in NF-κB activation and the consequent production of pro-inflammatory mediators that enhance the pathogenesis of SMA. Red arrows represent ligand-receptor interaction, black solid arrows represent activation, and dashed black arrows represent blockade. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Journal: EBioMedicine

Article Title: Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling

doi: 10.1016/j.ebiom.2019.06.040

Figure Lengend Snippet: LAIR1 signalling pathway in malaria. The LAIR1 pathway is activated by attachment of collagen and collagenous ligands (C1q) to LAIR1 extracellular surface. This results in phosphorylation of intracellular LAIR1 ITIM tyrosine residues by Src family kinases. Phosphorylated ITIMs serve as docking sites for recruitment of SHP-1 and SHP-2 phosphatases. SHP-1 and SHP-2 become localized to phosphorylated ITIMs through their regulatory SH2 domains, subsequently inducing their phosphatase activity. Activated SHP-1 has been shown to block activation and nuclear translocation of nuclear factor nuclear factor-kappa beta (NF-κB) through de-phosphorylation of inhibitor of kappa-beta kinase complex (IKK). SHP-1 phosphatase activity also inhibits activation and translocation of IRFs from the cytoplasm to the nucleus by preventing TANK-binding kinase 1 (TANK-1) phosphorylation of interferon regulatory factors (IRFs). These events subsequently block transcription of inflammatory mediator encoding genes with response elements for IRFs and NF-κB. SHP-2 inhibits activation of IRF 8 and blocks expression of phagocyte NADPH oxidase (gp91 PHOX ). LAIR1 inhibitory signalling is regulated by soluble LAIR1 and LAIR2 (soluble homolog of LAIR1) through competition for collagenous ligands. Children with SMA had increased circulating levels of sLAIR1 and sLAIR2 indicative of enhanced receptor shedding. C1q was reduced in children with SMA, thereby, limiting ligand availability. Phagocytosis of Pf Hz antagonizes LAIR1 signalling through down-regulation of LAIR1 ITIM and SHP-1 phosphorylation, but does not alter SHP-2 phosphorylation. Leukocytic ingestion of Pf Hz also decreases LAIR1 transcripts and protein. These events result in NF-κB activation and the consequent production of pro-inflammatory mediators that enhance the pathogenesis of SMA. Red arrows represent ligand-receptor interaction, black solid arrows represent activation, and dashed black arrows represent blockade. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Soluble LAIR1 was measured in serum of study participants using the human LAIR1 ELISA matched antibody pair, and recombinant human LAIR1 (Creative Diagnostics, 45–16 Ramsey Rd, Shirley, NY 11967; Cat No. ABPR-0519).

Techniques: Activity Assay, Blocking Assay, Activation Assay, Translocation Assay, De-Phosphorylation Assay, Binding Assay, Expressing

Relationship between LAIR1 expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.

Journal: EBioMedicine

Article Title: Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling

doi: 10.1016/j.ebiom.2019.06.040

Figure Lengend Snippet: Relationship between LAIR1 expression and intraleukocytic haemozoin. (a) Pairwise comparisons of LAIR1 transcript levels between children with and without pigment-containing monocytes (PCM) and pigment-containing neutrophils (PCN) in the non-SMA and SMA groups were determined using Mann-Whitney U test. Data are presented as box-plots, where the box represents the interquartile range, the line through the box is the median, and whiskers show the 10th and 90th percentiles. LAIR1 transcript levels were lower in children with PCM compared to those without, while LAIR1 transcript levels were comparable between absence/presence of PCN. (b) Temporal kinetics of LAIR1 transcript levels in response to Pf Hz treatment of PBMC from malaria-naïve donors ( n = 6, measured in triplicate). Pairwise comparisons were determined using Student t -test. Significant ( P < .05) differences in transcript levels between no treatment and Pf Hz treatment (10 μg/mL) groups represented by *at 0.5, 2, and 4 h time points. Data represent average of individuals ( n = 3) with each condition performed in triplicate (error bars represent SEM). (c) Immunoblot analysis of non-treated (baseline) and Pf Hz-treated (10 μg/mL) PBMC lysates for 12, 24, and 48 h. (d) Densitometric analysis of normalised cellular LAIR1 protein production presented as mean ± SEM. Across group comparisons analysed using ANOVA. Pairwise comparisons analysed using Student t-test. Data represent average of individuals ( n = 6) with each condition performed in triplicate (error bars represent SEM). LAIR1 protein levels were lower in Pf Hz-treated PBMC lysates compared to no treatment at 12, 24, and 24 h.

Article Snippet: Soluble LAIR1 was measured in serum of study participants using the human LAIR1 ELISA matched antibody pair, and recombinant human LAIR1 (Creative Diagnostics, 45–16 Ramsey Rd, Shirley, NY 11967; Cat No. ABPR-0519).

Techniques: Expressing, MANN-WHITNEY, Western Blot

Effect of intraleukocytic Pf Hz on LAIR1 and SHP-1 phosphorylation. Temporal kinetics of the signalling pathway in response to the different treatment conditions was determined in PBMCs from malaria-naïve donors (n = 6, measured in triplicate). (a) Human Phospho-immunoreceptor array results showing LAIR1 and SHP-1 phosphorylation upon no treatment (baseline), C1q (25 μg/mL), Pf Hz (10 μg/mL), and Pf Hz + C1q. Phosphorylation (spots) in the different conditions with control represented by blue boxes, LAIR1 by red boxes, and SHP-1 by green boxes. (b) Densitometric analysis of human phosphor-immunoreceptor array data. Data presented as (mean ± SEM). Across group comparisons analysed using ANOVA. *indicates significant differences ( P < .05) determined by Student t-test in pLAIR1 and pSHP-1 compared to C1q treatment. Phagocytosis of Pf Hz resulted in a reduction of pLAIR1 relative to C1q (alone) treatment. Similarly, ingestion of Pf Hz also caused a marked decrease in pSHP-1 levels relative to C1q treatment. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Journal: EBioMedicine

Article Title: Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling

doi: 10.1016/j.ebiom.2019.06.040

Figure Lengend Snippet: Effect of intraleukocytic Pf Hz on LAIR1 and SHP-1 phosphorylation. Temporal kinetics of the signalling pathway in response to the different treatment conditions was determined in PBMCs from malaria-naïve donors (n = 6, measured in triplicate). (a) Human Phospho-immunoreceptor array results showing LAIR1 and SHP-1 phosphorylation upon no treatment (baseline), C1q (25 μg/mL), Pf Hz (10 μg/mL), and Pf Hz + C1q. Phosphorylation (spots) in the different conditions with control represented by blue boxes, LAIR1 by red boxes, and SHP-1 by green boxes. (b) Densitometric analysis of human phosphor-immunoreceptor array data. Data presented as (mean ± SEM). Across group comparisons analysed using ANOVA. *indicates significant differences ( P < .05) determined by Student t-test in pLAIR1 and pSHP-1 compared to C1q treatment. Phagocytosis of Pf Hz resulted in a reduction of pLAIR1 relative to C1q (alone) treatment. Similarly, ingestion of Pf Hz also caused a marked decrease in pSHP-1 levels relative to C1q treatment. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Soluble LAIR1 was measured in serum of study participants using the human LAIR1 ELISA matched antibody pair, and recombinant human LAIR1 (Creative Diagnostics, 45–16 Ramsey Rd, Shirley, NY 11967; Cat No. ABPR-0519).

Techniques:

LAIR1 signalling pathway in malaria. The LAIR1 pathway is activated by attachment of collagen and collagenous ligands (C1q) to LAIR1 extracellular surface. This results in phosphorylation of intracellular LAIR1 ITIM tyrosine residues by Src family kinases. Phosphorylated ITIMs serve as docking sites for recruitment of SHP-1 and SHP-2 phosphatases. SHP-1 and SHP-2 become localized to phosphorylated ITIMs through their regulatory SH2 domains, subsequently inducing their phosphatase activity. Activated SHP-1 has been shown to block activation and nuclear translocation of nuclear factor nuclear factor-kappa beta (NF-κB) through de-phosphorylation of inhibitor of kappa-beta kinase complex (IKK). SHP-1 phosphatase activity also inhibits activation and translocation of IRFs from the cytoplasm to the nucleus by preventing TANK-binding kinase 1 (TANK-1) phosphorylation of interferon regulatory factors (IRFs). These events subsequently block transcription of inflammatory mediator encoding genes with response elements for IRFs and NF-κB. SHP-2 inhibits activation of IRF 8 and blocks expression of phagocyte NADPH oxidase (gp91 PHOX ). LAIR1 inhibitory signalling is regulated by soluble LAIR1 and LAIR2 (soluble homolog of LAIR1) through competition for collagenous ligands. Children with SMA had increased circulating levels of sLAIR1 and sLAIR2 indicative of enhanced receptor shedding. C1q was reduced in children with SMA, thereby, limiting ligand availability. Phagocytosis of Pf Hz antagonizes LAIR1 signalling through down-regulation of LAIR1 ITIM and SHP-1 phosphorylation, but does not alter SHP-2 phosphorylation. Leukocytic ingestion of Pf Hz also decreases LAIR1 transcripts and protein. These events result in NF-κB activation and the consequent production of pro-inflammatory mediators that enhance the pathogenesis of SMA. Red arrows represent ligand-receptor interaction, black solid arrows represent activation, and dashed black arrows represent blockade. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Journal: EBioMedicine

Article Title: Molecular basis of reduced LAIR1 expression in childhood severe malarial anaemia: Implications for leukocyte inhibitory signalling

doi: 10.1016/j.ebiom.2019.06.040

Figure Lengend Snippet: LAIR1 signalling pathway in malaria. The LAIR1 pathway is activated by attachment of collagen and collagenous ligands (C1q) to LAIR1 extracellular surface. This results in phosphorylation of intracellular LAIR1 ITIM tyrosine residues by Src family kinases. Phosphorylated ITIMs serve as docking sites for recruitment of SHP-1 and SHP-2 phosphatases. SHP-1 and SHP-2 become localized to phosphorylated ITIMs through their regulatory SH2 domains, subsequently inducing their phosphatase activity. Activated SHP-1 has been shown to block activation and nuclear translocation of nuclear factor nuclear factor-kappa beta (NF-κB) through de-phosphorylation of inhibitor of kappa-beta kinase complex (IKK). SHP-1 phosphatase activity also inhibits activation and translocation of IRFs from the cytoplasm to the nucleus by preventing TANK-binding kinase 1 (TANK-1) phosphorylation of interferon regulatory factors (IRFs). These events subsequently block transcription of inflammatory mediator encoding genes with response elements for IRFs and NF-κB. SHP-2 inhibits activation of IRF 8 and blocks expression of phagocyte NADPH oxidase (gp91 PHOX ). LAIR1 inhibitory signalling is regulated by soluble LAIR1 and LAIR2 (soluble homolog of LAIR1) through competition for collagenous ligands. Children with SMA had increased circulating levels of sLAIR1 and sLAIR2 indicative of enhanced receptor shedding. C1q was reduced in children with SMA, thereby, limiting ligand availability. Phagocytosis of Pf Hz antagonizes LAIR1 signalling through down-regulation of LAIR1 ITIM and SHP-1 phosphorylation, but does not alter SHP-2 phosphorylation. Leukocytic ingestion of Pf Hz also decreases LAIR1 transcripts and protein. These events result in NF-κB activation and the consequent production of pro-inflammatory mediators that enhance the pathogenesis of SMA. Red arrows represent ligand-receptor interaction, black solid arrows represent activation, and dashed black arrows represent blockade. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Soluble LAIR1 was measured in serum of study participants using the human LAIR1 ELISA matched antibody pair, and recombinant human LAIR1 (Creative Diagnostics, 45–16 Ramsey Rd, Shirley, NY 11967; Cat No. ABPR-0519).

Techniques: Activity Assay, Blocking Assay, Activation Assay, Translocation Assay, De-Phosphorylation Assay, Binding Assay, Expressing